- Highlights
- Chronic pancreatitis, which affects around three million people worldwide, is especially difficult to treat because the molecular drivers of the disease vary from patient to patient
- Salk researchers have created a new platform for studying chronic pancreatitis that retains patient-specific disease biology
- The platform can be used to develop personalized chronic pancreatitis treatments and has already pinpointed a protein that could be a promising target for many patients
LA JOLLA—Around three million people worldwide struggle with chronic pancreatitis, a condition wherein the pancreas becomes inflamed, scarred, and painful. There is no cure for chronic pancreatitis, and it is difficult to alter the disease trajectory after onset.
Click here for a high-resolution image.
Credit: Salk Institute
Salk scientists are hoping to change that. In a new study…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
